Patrick Loustau

Patrick Loustau

Merck KGaA : Merck Announces Further Management Changes to Drive Pharmaceutical Business Growth | 4-...

Bristol-Myers Squibb - " As part of the organizational changes at Merck Serono, the company also appointed Dr. Annalisa Jenkins, MBBS, MRCP, currently Head of Global Development and Medical, as Head of Global Research & Development, effective October 1. Under her leadership, Merck Serono aims to further ...

Annalisa Jenkins

Mentioned in this article:
Annalisa Jenkins

Stephen Sadove to join JCPenney board of directors | Positions and Promotions

Bristol-Myers Squibb - October 10, 2013, Plano, Tx., USA - J. C. Penney Company, Inc. announced that Stephen I. Sadove has been elected to its board of directors. Mr. Sadove is currently chairman and chief executive officer of Saks Incorporated and will be leaving Saks upon completion of its previously ...

Stephen Sadove

Mentioned in this article:
Stephen Sadove

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) Investor Alert: Investigation over Possible Vio...

Bristol-Myers Squibb - On January 1, 2013, Teva Pharmaceutical Industries Ltd announced that that Shlomo Yanai, President and CEO of Teva Pharmaceutical Industries Ltd, planed to retire from the company effective May 2012, and that as part of a succession plan, the Board of Directors has named Dr. Jeremy ...

Dr. Jeremy M. Levin

Mentioned in this article:
Dr. Jeremy M. Levin

Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb to Present at Cowen and Company 34th...

Brian Daniels, senior vice president, Global Development and Medical Affairs, will make a formal presentation about the company at 10 a.m. Bristol-Myers Squibb Company (BMY), currently valued at $88.86B, began trading this morning at $53.63. Looking at the equity, the company’s one day ...

Brian Daniels

Mentioned in this article:
Brian Daniels

John Celentano Joins YourEncore Board of Directors - Yahoo Finance

Bristol-Myers Squibb - ... and Transforming Life Sciences Companies YourEncore, a leading provider of expert advisory and execution services to the life sciences, consumer health and nutrition industries, today announced that pharmaceutical industry veteran John E. Celentano has joined the company’s board of directors...

John E. Celentano

Mentioned in this article:
John E. Celentano

New drug combo cures toughest cases of hepatitis C, hints to future injection-free therapies

Bristol-Myers Squibb - Rajender Reddy, Tarek Hassanein, Ira Jacobson, Eric Lawitz, Anna S. Lok, Federico Hinestrosa, Paul J. Thuluvath, Howard Schwartz, David R. Nelson, Gregory T. Everson, Timothy Eley, Megan Wind-Rotolo, Shu-Pang Huang, Min Gao, Dennis Hernandez, Fiona McPhee, Diane Sherman, Robert Hindes...

Megan Wind-Rotolo

Mentioned in this article:
Megan Wind-Rotolo

Bristol-Myers Squibb Canada | Bristol-Myers Squibb's innovative melanoma treatment Yervoy receives i...

"We are very proud of the difference Yervoy has made, and will continue to make, in the lives of Canadians with metastatic melanoma and their families," said Awny Farajallah, Vice-President, Medical, Bristol-Myers Squibb Canada. "Yervoy represents the important progress we have made in ...

Awny Farajallah

Mentioned in this article:
Awny Farajallah

3rd Annual Gross-to-Net Accounting & Accruals | Healthcare Finance News

Bristol-Myers Squibb - Led by Distinguished Chairman David Levi of Bristol-Myers Squibb, Don’t miss the industry event that convenes over 200 GTN Accounting and Finance executives each year! Pharmaceutical manufacturers are tasked with a huge volume of transactions and contracts. These are complex, often ...

David Levi, CPA

Mentioned in this article:
David Levi, CPA

Ambrx Appoints Peter Kiener, Ph.D., as Chief Scientific Officer -- SAN DIEGO, Aug. 20, 2013 /PRNews...

Bristol-Myers Squibb - SAN DIEGO, Aug. 20, 2013 /PRNewswire/ -- Ambrx today announced the appointment of Peter Kiener, Ph.D., as chief scientific officer. Dr. Kiener brings decades of expertise in the development of next-generation biologic therapeutics, including multi-specific, antibody based ...

Peter Kiener

Mentioned in this article:
Peter Kiener

Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial Results -- SAN DIEGO, M...

Bristol-Myers Squibb - Ted Schroeder, President and CEO of Cadence, stated, "Our fourth quarter 2012 revenue exceeded our guidance as we ended the year with strong sales growth and momentum. We continue to expand our customer base and drive higher OFIRMEV utilization rates as physicians increasingly recognize ...

Ted Schroeder

Mentioned in this article:
Ted Schroeder

Join Newsle to find out when Patrick Loustau makes the news.

As a Newsle member, you’ll be able to:

  • Get alerts on Patrick Loustau
  • See news articles & blog posts about Patrick Loustau
  • Follow your friends & colleagues in the news
This profile only includes publicly available information. Questions or comments? Contact Us
Freebase CC-BY
Data from Freebase, licensed under CC-BY
Source: CrunchBase
Data from Wikipedia, licensed under the GFDL